Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens

NCT: NCT05886348 · ACTIVE_NOT_RECRUITING

NCT IDNCT05886348
StatusACTIVE_NOT_RECRUITING
Start Date2023-07-31
Completion2027-05-31
SponsorHOYA Lens Thailand LTD. (INDUSTRY)
First posted
Last updated

Brief Summary

The goal of this clinical trial is to test Novel spectacle lenses in myopic children. The main question it aims to answer are: safety and efficacy of the lenses. Participants will be asked to wear spectacles and participate in eye exams and questionnaires. Researchers will compare Novel spectacle lenses and general single vision spectacle lenses to see if the Novel spectacle lenses correct myopic ametropia, slow the progression of myopia and axial elongation.

Frequently Asked Questions

What is The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens?

The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens is a clinical trial registered under NCT05886348. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05886348?

The current status of NCT05886348 (The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens) is: ACTIVE_NOT_RECRUITING.

When did The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens start?

The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens started on 2023-07-31.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.